Lepodisiran Sodium + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease (ASCVD)
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Trial Timeline
Mar 5, 2024 → Mar 1, 2029
NCT ID
NCT06292013About Lepodisiran Sodium + Placebo
Lepodisiran Sodium + Placebo is a phase 3 stage product being developed by Eli Lilly for Atherosclerotic Cardiovascular Disease (ASCVD). The current trial status is active. This product is registered under clinical trial identifier NCT06292013. Target conditions include Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06292013 | Phase 3 | Active |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease (ASCVD)